Davis Polk advised Warner Chilcott plc in connection with an SEC-registered offering of 25,000,000 of its ordinary shares by certain selling shareholders for an aggregate price to the public of approximately $581 million. The selling shareholders included funds affiliated with Bain Capital Partners, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners, as well as members of the company’s senior management. The ordinary shares are listed on Nasdaq.

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.

The Davis Polk corporate team included partner Michael Kaplan and associates Sophia Hudson and Adam Rachlis. The tax team included partner Michael Mollerus and associates Craig A. Phillips and Rachel Lerner (not yet admitted). Partner Edmond T. FitzGerald and associate Gillian Emmett Moldowan provided benefits advice. Catherine L. Martin provided 1940 Act advice. Natalie Chan was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.